RU2013120607A - METHOD FOR INDIRECT ASSESSMENT OF SENSITIVITY OF LUNG CANCER CELLS TO DOXORUBICIN ON THE BASIS OF EXPRESSION LEVELS OF MARKER GENES AND KIT FOR ITS IMPLEMENTATION - Google Patents

METHOD FOR INDIRECT ASSESSMENT OF SENSITIVITY OF LUNG CANCER CELLS TO DOXORUBICIN ON THE BASIS OF EXPRESSION LEVELS OF MARKER GENES AND KIT FOR ITS IMPLEMENTATION Download PDF

Info

Publication number
RU2013120607A
RU2013120607A RU2013120607/10A RU2013120607A RU2013120607A RU 2013120607 A RU2013120607 A RU 2013120607A RU 2013120607/10 A RU2013120607/10 A RU 2013120607/10A RU 2013120607 A RU2013120607 A RU 2013120607A RU 2013120607 A RU2013120607 A RU 2013120607A
Authority
RU
Russia
Prior art keywords
sensitivity
lung cancer
expression levels
cancer cells
marker genes
Prior art date
Application number
RU2013120607/10A
Other languages
Russian (ru)
Other versions
RU2528247C2 (en
Inventor
Кирилл Никитич Кашкин
Екатерина Владимировна Барсова
Герман Александрович Шипулин
Татьяна Александровна Чеканова
Елена Александровна Пудова
Надежда Васильевна Скапцова
Виктор Кузьмич Потапов
Евгений Павлович Копанцев
Марина Валерьевна Зиновьева
Татьяна Викторовна Виноградова
Original Assignee
Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН)
Федеральное государственное бюджетное учреждение науки Центральный научно-исследовательский институт эпидемиологии
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН), Федеральное государственное бюджетное учреждение науки Центральный научно-исследовательский институт эпидемиологии filed Critical Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН)
Priority to RU2013120607/10A priority Critical patent/RU2528247C2/en
Publication of RU2013120607A publication Critical patent/RU2013120607A/en
Application granted granted Critical
Publication of RU2528247C2 publication Critical patent/RU2528247C2/en

Links

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

1. Способ косвенной оценки чувствительности клеток рака легкого к доксорубицину на основании уровней экспрессии маркерных генов ABCC1, ERCC1, FTL, GSTP1, МТ2А, RRM1, TUBB3, которые определяют с помощью гибридизации флуоресцентно меченых препаратов нуклеиновых кислот, приготовленных из клеток, со специфическими олигонуклеотидными зондами, иммобилизованными на твердой подложке.2. Набор специфических олигонуклеотидных зондов, предназначенных для осуществления изобретения.1. A method for indirectly evaluating the sensitivity of lung cancer cells to doxorubicin based on the expression levels of marker genes ABCC1, ERCC1, FTL, GSTP1, MT2A, RRM1, TUBB3, which are determined by hybridization of fluorescently labeled nucleic acid preparations prepared from cells with specific oligonucleotide probes immobilized on a solid substrate. 2. A set of specific oligonucleotide probes for carrying out the invention.

Claims (2)

1. Способ косвенной оценки чувствительности клеток рака легкого к доксорубицину на основании уровней экспрессии маркерных генов ABCC1, ERCC1, FTL, GSTP1, МТ2А, RRM1, TUBB3, которые определяют с помощью гибридизации флуоресцентно меченых препаратов нуклеиновых кислот, приготовленных из клеток, со специфическими олигонуклеотидными зондами, иммобилизованными на твердой подложке.1. A method for indirectly evaluating the sensitivity of lung cancer cells to doxorubicin based on the expression levels of marker genes ABCC1, ERCC1, FTL, GSTP1, MT2A, RRM1, TUBB3, which are determined by hybridization of fluorescently labeled nucleic acid preparations prepared from cells with specific oligonucleotide probes immobilized on a solid substrate. 2. Набор специфических олигонуклеотидных зондов, предназначенных для осуществления изобретения. 2. A set of specific oligonucleotide probes for carrying out the invention.
RU2013120607/10A 2013-05-07 2013-05-07 Method of evaluation of sensitivity of lung cancer cells to doxorubicin based on expression levels of marker genes and set for its implementation RU2528247C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2013120607/10A RU2528247C2 (en) 2013-05-07 2013-05-07 Method of evaluation of sensitivity of lung cancer cells to doxorubicin based on expression levels of marker genes and set for its implementation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2013120607/10A RU2528247C2 (en) 2013-05-07 2013-05-07 Method of evaluation of sensitivity of lung cancer cells to doxorubicin based on expression levels of marker genes and set for its implementation

Publications (2)

Publication Number Publication Date
RU2013120607A true RU2013120607A (en) 2013-09-27
RU2528247C2 RU2528247C2 (en) 2014-09-10

Family

ID=49253802

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013120607/10A RU2528247C2 (en) 2013-05-07 2013-05-07 Method of evaluation of sensitivity of lung cancer cells to doxorubicin based on expression levels of marker genes and set for its implementation

Country Status (1)

Country Link
RU (1) RU2528247C2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108866185A (en) * 2017-05-16 2018-11-23 肿瘤学风险公司 Method for predicting the medicine response in cancer patient

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
FI3198035T3 (en) 2014-09-26 2023-01-31 Methods for predicting drug responsiveness
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010059742A1 (en) * 2008-11-18 2010-05-27 Collabrx, Inc. Individualized cancer treatment
ES2763899T3 (en) * 2009-07-08 2020-06-01 Worldwide Innovative Network Method for predicting drug efficacy in a patient
WO2012024543A1 (en) * 2010-08-18 2012-02-23 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
RU2458131C1 (en) * 2010-12-07 2012-08-10 Федеральное бюджетное учреждение науки Институт молекулярной биологии им.В.А.Энгельгардта Test system for mutation detection in human fumarylacetoacetate hydrolase and alpha-1-antitrypsin genes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108866185A (en) * 2017-05-16 2018-11-23 肿瘤学风险公司 Method for predicting the medicine response in cancer patient

Also Published As

Publication number Publication date
RU2528247C2 (en) 2014-09-10

Similar Documents

Publication Publication Date Title
MX367666B (en) Compositions and methods for quantifying a nucleic acid sequence in a sample.
EA202090290A1 (en) APPLICATION OF PROTEIN Cas, METHOD FOR DETECTING TARGET NUCLEIC ACID MOLECULE AND KIT
GB2526736A (en) Methods, compositions, and kits for nucleic acid analysis
AU2017257624A1 (en) Hybridization chain reaction methods for in situ molecular detection
EA201692157A1 (en) SYNTHESIS OF TWO-CELLULAR NUCLEIC ACIDS
BR112017008082A2 (en) compositions and methods for detecting an rna virus
AR102518A1 (en) METHODS AND BIOMARKERS TO PREACH THE EFFECTIVENESS AND EVALUATION OF AN OX40 AGONIST TREATMENT
EA201492114A1 (en) COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION
WO2014182528A3 (en) Multiplex labeling of molecules by sequential hybridization barcoding
MX2019007814A (en) Gene expression profile algorithm and test for determining prognosis of prostate cancer.
EA201600085A1 (en) KIT FOR DETECTION OF SOYO SYNT SYNT0H2 EVENT
WO2014144657A3 (en) Compositions and methods for cancer prognosis
RU2013120607A (en) METHOD FOR INDIRECT ASSESSMENT OF SENSITIVITY OF LUNG CANCER CELLS TO DOXORUBICIN ON THE BASIS OF EXPRESSION LEVELS OF MARKER GENES AND KIT FOR ITS IMPLEMENTATION
EA201492123A1 (en) COMPOSITIONS AND METHODS FOR MODULATING THE EXPRESSION OF THE SMN GENES FAMILY
BR112013010856A2 (en) test for gardnerella vaginalis
EA201201036A1 (en) TARGETED GENOMIC CHANGES
MX2017001405A (en) Detection of target nucleic acids using hybridization.
TR201819546T4 (en) Determination methods for specimen species origin.
BR112015023769A2 (en) analytical instrument systems
UA115321C2 (en) Methods and compositions for analyzing ahasl genes in wheat
EA201990730A1 (en) RNA BIOMARKERS FOR HEREDITARY ANGIONEUROTIC Edema
WO2016059473A3 (en) Sequence conversion and signal amplifier dna having locked nucleic acids and detection methods using same
BR112013004044A2 (en) compositions and methods for quantifying a nucleic acid sequence in a sample.
MX369911B (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer.
GB2542576A (en) Method and kit of detecting the absence of micro-oranisms